风险最小化执行方案的制定和完善的技术指导原则

2008-05-08 国家药品监督管理局药品审评中心（CDE） CDE

风险最小化执行方案的制定和完善的技术指导原则

中文标题：

发布机构：

国家药品监督管理局药品审评中心（CDE）

发布日期：

2008-05-08

简要介绍：

风险最小化执行方案的制定和完善的技术指导原则

相关资料下载：

风险最小化执行方案的制定和完善的技术指导原则.pdf

下载请点击：

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
2021-07-05 ms2000001898877799

hhhh

111 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
2021-07-04 微探

为了更好地学习和推广，建议少扣或不扣积分，谢谢

115 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
2021-07-03 ms4000001832228962

很好很实用

100 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=996462, encodeId=c15c99646264, content=hhhh, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dad5539561, createdName=ms2000001898877799, createdTime=Mon Jul 05 16:36:46 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995996, encodeId=b896995996b5, content=为了更好地学习和推广，建议少扣或不扣积分，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Jul 04 08:52:54 CST 2021, time=2021-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995571, encodeId=145b9955e193, content=很好很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c175540100, createdName=ms4000001832228962, createdTime=Sat Jul 03 01:07:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978634, encodeId=0e969e86343e, content=真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3705526517, createdName=ACU97, createdTime=Thu Jul 01 15:38:38 CST 2021, time=2021-07-01, status=1, ipAttribution=)]
2021-07-01 ACU97

真好

122 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

指南&解读指南

风险最小化执行方案的制定和完善的技术指导原则

相关指南

科室

工具

服务